Literature DB >> 26970830

Volume Overload Profiles in Patients With Preserved and Reduced Ejection Fraction Chronic Heart Failure: Are There Differences? A Pilot Study.

Wayne L Miller1, Brian P Mullan2.   

Abstract

OBJECTIVES: This study aimed to characterize volume profiles and their differences in heart failure (HF) patients with preserved (HFpEF) and reduced (HFrEF) ventricular systolic function.
BACKGROUND: The extent and distribution of volume overload and the associated implications for volume management have not been studied in decompensated HFpEF compared with HFrEF.
METHODS: Total blood volume (TBV) was quantitated using a standardized computer-based radiolabeled albumin dilution technique.
RESULTS: Twenty HFpEF and 35 HFrEF patients were evaluated at hospital admission. TBV was expanded by 27 ± 21% (range -5.2% to 77%; p = 0.002) and 37 ± 25% (0% to 107%; p < 0.001), respectively, above normal volumes. Red cell mass (RBCM) was expanded in HFrEF (24 ± 31%; p = 0.004) but within normal limits in HFpEF (8 ± 34%; p = 0.660) with, however, large variability in both groups. RBCM excess was more prominent in HFrEF (63% vs. 45%) than the RBCM deficit in HFpEF (35% vs.14%). With diuresis, TBV decreased to 25 ± 20% (p = 0.029) in HFrEF but was not changed in HFpEF (18 ± 20% [p = 0.173]). Body weight declined 6.6 ± 4.4 kg in HFrEF and 10.5 ± 8.3 kg (p = 0.026) in HFpEF. Interstitial fluid losses accounted for 85 ± 13% (HFrEF) and 93 ± 6% (HFpEF) (p = 0.012) of total volume removed.
CONCLUSIONS: TBV profiles differ between HFpEF and HFrEF patients with DCHF. Quantitated volume analysis revealed both significant RBCM (polycythemia) and plasma volume excess in HFrEF, whereas a higher RBCM deficit (true anemia) was demonstrated in HFpEF. Diuresis produced only a modest reduction in intravascular volumes with persistent hypervolemia in both groups at discharge, but overall more total body fluid was lost in HFpEF. These profile differences have implications for individualizing volume management.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  HFpEF; HFrEF; decompensated chronic heart failure; diuretic therapy; total blood volume quantitation; volume overload

Mesh:

Substances:

Year:  2016        PMID: 26970830     DOI: 10.1016/j.jchf.2016.01.005

Source DB:  PubMed          Journal:  JACC Heart Fail        ISSN: 2213-1779            Impact factor:   12.035


  19 in total

Review 1.  Cardiorenal syndrome in heart failure with preserved ejection fraction-an under-recognized clinical entity.

Authors:  Akanksha Agrawal; Mario Naranjo; Napatt Kanjanahattakij; Janani Rangaswami; Shuchita Gupta
Journal:  Heart Fail Rev       Date:  2019-07       Impact factor: 4.214

Review 2.  Heart failure with preserved ejection fraction: a nephrologist-directed primer.

Authors:  Baris Afsar; Patrick Rossignol; Loek van Heerebeek; Walter J Paulus; Kevin Damman; Stephane Heymans; Vanessa van Empel; Alan Sag; Alan Maisel; Mehmet Kanbay
Journal:  Heart Fail Rev       Date:  2017-11       Impact factor: 4.214

Review 3.  Obstructive Ventilatory Disorder in Heart Failure-Caused by the Heart or the Lung?

Authors:  Sergio Caravita; Jean-Luc Vachiéry
Journal:  Curr Heart Fail Rep       Date:  2016-12

4.  Optimal Endpoints of Acute Heart Failure Therapy.

Authors:  Jessica H Huston; Robinson Ferre; Peter S Pang; Ovidiu Chioncel; Javed Butler; Sean Collins
Journal:  Am J Ther       Date:  2018 Jul/Aug       Impact factor: 2.688

Review 5.  Estimated plasma volume status in heart failure: clinical implications and future directions.

Authors:  Masatake Kobayashi; Nicolas Girerd; Kevin Duarte; Tahar Chouihed; Taishiro Chikamori; Bertram Pitt; Faiez Zannad; Patrick Rossignol
Journal:  Clin Res Cardiol       Date:  2021-01-06       Impact factor: 5.460

6.  Time course of red cell volume and plasma volume over six months in compensated chronic heart failure.

Authors:  Christoph Ahlgrim; Florian Seiler; Philipp Birkner; Dawid Leander Staudacher; Sebastian Grundmann; Christoph Bode; Torben Pottgiesser
Journal:  ESC Heart Fail       Date:  2021-01-05

7.  Age-dependent impairment of the erythropoietin response to reduced central venous pressure in HFpEF patients.

Authors:  David Montero; Thomas Haider; Jens Barthelmes; Jens P Goetze; Silviya Cantatore; Carsten Lundby; Isabella Sudano; Frank Ruschitzka; Andreas J Flammer
Journal:  Physiol Rep       Date:  2019-03

8.  Impact of Systemic Volume Status on Cardiac Magnetic Resonance T1 Mapping.

Authors:  Marlies Antlanger; Stefan Aschauer; Andreas A Kammerlander; Franz Duca; Marcus D Säemann; Diana Bonderman; Julia Mascherbauer
Journal:  Sci Rep       Date:  2018-04-03       Impact factor: 4.379

9.  Different effects of SGLT2 inhibitors according to the presence and types of heart failure in type 2 diabetic patients.

Authors:  In-Chang Hwang; Goo-Yeong Cho; Yeonyee E Yoon; Jin Joo Park; Jun-Bean Park; Seung-Pyo Lee; Hyung-Kwan Kim; Yong-Jin Kim; Dae-Won Sohn
Journal:  Cardiovasc Diabetol       Date:  2020-05-28       Impact factor: 9.951

10.  Blood volume measurement using cardiovascular magnetic resonance and ferumoxytol: preclinical validation.

Authors:  Rajiv Ramasawmy; Toby Rogers; Miguel A Alcantar; Delaney R McGuirt; Jaffar M Khan; Peter Kellman; Hui Xue; Anthony Z Faranesh; Adrienne E Campbell-Washburn; Robert J Lederman; Daniel A Herzka
Journal:  J Cardiovasc Magn Reson       Date:  2018-09-10       Impact factor: 5.364

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.